Insider Transactions in Q4 2022 at Phreesia, Inc. (PHR)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2022
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
242
+0.24%
|
$5,082
$21.63 P/Share
|
|
Dec 20
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
378
-0.43%
|
$12,474
$33.73 P/Share
|
|
Dec 20
2022
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+14.64%
|
$0
$0.84 P/Share
|
|
Dec 17
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Indirect |
15
-0.27%
|
$495
$33.97 P/Share
|
|
Dec 16
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Indirect |
36
-0.64%
|
$1,188
$33.97 P/Share
|
|
Dec 14
2022
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
801
-0.78%
|
$28,836
$36.0 P/Share
|
|
Dec 13
2022
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
11,377
-5.78%
|
$386,818
$34.61 P/Share
|
|
Dec 13
2022
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,109
-2.93%
|
$105,706
$34.4 P/Share
|
|
Dec 12
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,395
-6.38%
|
$229,245
$31.77 P/Share
|
|
Dec 09
2022
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
26,837
-12.0%
|
$778,273
$29.77 P/Share
|
|
Dec 09
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,934
-3.99%
|
$298,020
$30.79 P/Share
|
|
Nov 06
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,636
-4.29%
|
$135,264
$24.34 P/Share
|
|
Nov 02
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
19,341
-7.46%
|
$522,207
$27.18 P/Share
|
|
Oct 31
2022
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
366
+1.56%
|
$9,882
$27.32 P/Share
|
|
Oct 31
2022
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
366
+0.97%
|
$9,882
$27.32 P/Share
|
|
Oct 31
2022
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
366
+1.62%
|
$9,882
$27.32 P/Share
|
|
Oct 18
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
1,075
-1.0%
|
$26,875
$25.26 P/Share
|
|
Oct 14
2022
|
Evan Roberts Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,140
-0.3%
|
$47,080
$22.48 P/Share
|
|
Oct 14
2022
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-0.67%
|
$13,706
$22.48 P/Share
|
|
Oct 14
2022
|
Randy Rasmussen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,219
-0.92%
|
$26,818
$22.48 P/Share
|
|
Oct 14
2022
|
David Linetsky SVP, Life Sciences |
SELL
Payment of exercise price or tax liability
|
Direct |
1,749
-0.78%
|
$38,478
$22.48 P/Share
|
|
Oct 14
2022
|
Chaim Indig Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,660
-0.29%
|
$80,520
$22.48 P/Share
|
|
Oct 14
2022
|
Allison C Hoffman General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,128
-1.05%
|
$24,816
$22.48 P/Share
|
|
Oct 14
2022
|
Michael J. Davidoff SVP, Payer Business |
SELL
Payment of exercise price or tax liability
|
Direct |
1,123
-1.04%
|
$24,706
$22.48 P/Share
|